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Abstract
ATP-sensitive potassium (K ATP ) channels are abundantly expressed in the myocardium.
Although a definitive role for the channel remains elusive they have been implicated in the phenomenon of cardioprotection, but the precise mechanism is unclear. We set out to test the hypothesis that the channel protects by opening early during ischemia to shorten action potential duration and reduce electrical excitability thus sparing intracellular ATP. This could reduce reperfusion injury by improving calcium homeostasis.
Using a combination of contractile function analysis, calcium fluorescence imaging and patch clamp electrophysiology in cardiomyocytes isolated from adult male Wistar rats, we demonstrated that the opening of sarcolemmal K ATP channels was markedly delayed after cardioprotective treatments; ischemic preconditioning, adenosine and PMA. This was due to the preservation of intracellular ATP for longer during simulated ischemia therefore maintaining sarcolemmal K ATP channels in the closed state for longer. As the simulated ischemia progressed, K ATP channels opened to cause contractile, calcium transient and action potential failure, however there was no indication of any channel activity early during simulated ischemia to impart an energy sparing hyperpolarization or action potential shortening.
We present compelling evidence to demonstrate that early opening of sarcolemmal K ATP channels during simulated ischemia is not part of the protective mechanism imparted by ischemic preconditioning or other PKC-dependent cardioprotective stimuli. On the contrary, channel opening was actually delayed. We conclude that sarcolemmal K ATP channel opening is a consequence of ATP depletion, not a primary mechanism of ATP preservation in these cells.
Highlights:
• Opening of the SarcoK ATP channel was proposed to be cardioprotective
• Channel opening was delayed after cardioprotective stimuli
• Ca 2+ & ATP levels were maintained during ischemia independent of SarcoK ATP opening
• Mitochondrial function preserved during ischemia, independent of SarcoK ATP opening
• Early opening of SarcoK ATP is not involved in PKC-dependent cardioprotection
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Introduction:
ATP-sensitive potassium (K ATP ) channels are abundantly expressed throughout the myocardium, however a definitive role in myocardial function has yet to be fully elucidated [1] . K ATP channels are ubiquitously expressed protein complexes hypothesized to provide a link between metabolic state and electrical excitability by virtue of their inhibition by ATP at normal physiological concentrations following direct binding of ATP to the Kir6 pore-forming subunit. In normal physiological conditions the channel is predominantly inhibited, whilst a fall in the ATP:ADP ratio causes activation.
The K ATP channel is expressed as a hetero-octameric structure comprising four Kir6 (Kir6.1 or Kir6.2) and four sulphonylurea (SUR) subunits (SUR1 or SUR2). SUR2 has two predominant splice variants SUR2A and 2B. Two K ATP channel subtypes have been proposed in the heart; the sarcolemmal (sarcoK ATP ) and mitochondrial (mitoK ATP ). The cardiac ventricular sarcoK ATP channel has been identified as comprising Kir6.2 and SUR2A
as the predominant subunit combination [2] [3] [4] . Other K ATP subunits are expressed in cardiomyocytes and may form components of the postulated mitoK ATP [4] .
An early hypothesis used to define the role of K ATP channels suggested that during an ischemic insult, activation of the sarcoK ATP channel by a depletion of ATP and concurrent elevation in ADP, would cause a shortening of the cardiac action potential duration (APD) [5] and might lead to complete action potential failure, as the weakly rectifying K ATP channel activity short-circuited the triggered depolarization. These actions could limit the rise in intracellular calcium and preserve cellular ATP. Several studies attempted to address the relationship between APD and cardioprotection at the whole organ level (for example Yao 1994 [6] , Grover 1995[7] ) but these relied on responses to pharmacological agents to infer K ATP activity and provided little information about what was happening to APD, the calcium or membrane potential of individual cardiomyocytes.
Following Murray's description of ischemic preconditioning (IPC), as the intrinsic ability of the myocardium to be protected from a prolonged ischemic insult by a series of short ischemic episodes prior to the main insult [8] , pharmacological agents have been used to both implicate and exclude K ATP channel involvement in the protection afforded by ischemic preconditioning and other cardioprotective stimuli [9] [10] [11] [12] . The definitive mechanism behind this remarkable intrinsic protection still remains elusive with an increasingly complex, and often contradictory, literature. Recently, protein kinases forming part of the RISK pathway, specifically PKCε, have been implicated in the IPC phenomenon [13] . Experimentally, in cardioprotective protocols, PKCε is translocated to the mitochondria [13] [14] [15] . It has been demonstrated in differing tissue types that K ATP channels can be regulated by a number of different cell signaling pathways; in particular by PKA and PKC [16] . However, the mechanism by which either of the cardiac K ATP channel subtypes may be directly involved in the protection afforded by IPC, or other cardioprotective stimuli, is still unclear [17] .
Evidence for a key role for the cardiac K ATP channel comes from the observation that pharmacological blockade [12, 18] , disruption of channel expression with interacting fragments of SUR [19] , shRNA knockdown [3] and knockout of Kir6.2 subunits [20, 21] all have deleterious effects on the ability of IPC and other cardioprotective stimuli to impart protection.
The importance of the sarcoK ATP in IPC has been the subject of much debate since the existence of a mitochondrial K ATP (mitoK ATP ) channel was first hypothesized [22] . 
Patch-clamp electrophysiology
Action potential and cell-attached patch recordings were made as previously described [19] . displaying a cardioprotected phenotype may be prepared using a "stop-start" perfusion protocol in a whole heart mounted on a Langendorff perfusion system prior to enzymatic isolation of cardiomyocytes [27] . Using the metabolic inhibition and reperfusion (MI/R) protocol with the isolated cardiomyocytes, the degree of cardioprotection can be assessed by measuring the proportion of cells recovering contractile function at the end of a period of simulated reperfusion and also by measuring the proportion of hypercontracted cardiomyocytes, as a surrogate measure of reperfusion injury. This protocol gives levels of hypercontracture in isolated cardiomyocytes similar to infarct size in the whole heart reported in the literature (up to 40% of the area at risk in control, and as low as 10% after cardioprotective stimuli) [9, 31] . Furthermore, using this protocol, the contractile function of the cardiomyocytes can be measured throughout the periods of metabolic inhibition and reperfusion. This gives additional functional data, which cannot be recorded using other protocols, such as ischemic pelleting, whilst reproducing the survival data obtained using such techniques.
Cardiomyocytes were pre-treated with cardioprotective agents by perfusion with Tyrode's solution (2CaT) containing either 100 μmol/L diazoxide, 50 μmol/L pinacidil or 100 μmol/L adenosine for 5 minutes followed by wash out with 2CaT in the first 3 minutes of the MI/R protocol prior to substrate-free metabolic inhibition Tyrode's (SFT-MI) perfusion. For direct PKC activation, 5 μmol/L phorbol 12-myristate 13-acetate (PMA) was added to the perfusion chamber and cardiomyocytes incubated for 5 minutes prior to starting the 2CaT perfusion for 5 minutes leading into the MI/R protocol. Figure 1A including direct PKC activation with PMA, the contractile recovery was greater than control.
Pre-treatment with 5-HD (500 µmol/L), a postulated mitoK ATP channel inhibitor [32] , had no effect on the time to contractile failure or on the contractile recovery on reperfusion compared to control. Figure 1B normalized, a longer SFT-MI period was used after pre-treatment with these agents.
Significant cardioprotection, as assessed by an increased percentage contractile recovery and reduced hypercontracture, was still observed using a '9 minute SFT-MI' protocol in pinacidil and adenosine pre-treated cardiomyocytes, but not in those pre-treated with diazoxide ( Figure 2A and B) when compared to the '7 minute SFT-MI' control group.
Although the CN/IAA SFT-MI model employed in this study is widely used, we tested our findings using an 'ischaemic buffer'. This buffer was designed to mimic conditions seen in ischaemia more than just a simple substrate removal/metabolic poison. This model used a high K + , low pH, non-metabolized deoxyglucose, high lactate solution with the addition of the mitochondrial uncoupler (DNP). Our findings of a delayed time to contractile failure in adenosine, pinacidil and PMA were replicated in this model ( Figure 2C ). The time to contractile failure was not significantly different after diazoxide pre-treatment, as in the CN/IAA model ( Figure 2C ). The contractile recovery was increased ( Figure 2D ) and the hypercontracture, as confirmed by Trypan blue uptake ( Figure 2E ), was decreased consistent with the findings reported in the CN/IAA model in figure 1.
The time to action potential failure during metabolic inhibition was associated
with the activity of PKCε.
Figure 1B, Figure 2C -E, and our previous findings [26] , showed that direct activation of PKC by PMA imparts a cardioprotected-like phenotype to cardiomyocytes. Tat-peptide linked PKC isoform-specific inhibitor peptides were used to dissect the contribution of specific PKC isoforms to the delay in action potential failure. Isolated cardiomyocytes were incubated with Tat-PKC inhibitors (100 nmol/L) for 10 minutes, followed by a further 5 minutes with 5 μmol/L PMA prior to experimentation. Cardiomyocytes were then perfused for 10 minutes with 2CaT prior to metabolic inhibition with SFT-MI solution. Action potentials were stimulated at 1 Hz via the patch pipette and the APD 90 and time to action potential failure recorded. In cardiomyocytes pipette-loaded with the scrambled peptide, the time to action potential failure after PMA treatment was significantly increased compared to PKCε inhibitor peptide loaded via the patch-pipette and control cardiomyocytes ( Figure 3A and B). Figure 3C shows the mean time to action potential failure on selective inhibition of PKC isoforms after PMA treatment. PMA treatment delayed action potential failure in isolated cardiomyocytes, except for cells treated with PKCε or non-specific (20-28) peptide inhibitors. Additionally, if PKCε was activated directly using a Tat-ψRACKε activating peptide [13, 33] Mirroring the attenuation of the increase in time to action potential failure, the increase in time to hyperpolarization was also attenuated by inhibition of PKCε using Tat-PKCε inhibitor peptide (Tat-PKCε-IP). In the absence of metabolic inhibition, only pinacidil affected the action potential duration or the membrane potential of cardiomyocytes acutely or after a pretreatment ( Figure 4C ).
Cardioprotection by IPC, adenosine and diazoxide, but not pinacidil, is attenuated by PKCε inhibition.
Having shown that the delay in action potential failure was PKCε-dependent, we investigated the effect of inhibiting PKCε on cardioprotection using contractile function measurements.
As expected Tat-PKCε-IP attenuated the delay in contractile failure seen in IPC, PMAtreated and adenosine treated cardiomyocytes ( Figure 5A ). Inhibition of PKCε markedly reduced the contractile recovery and attenuated the reduction in hypercontracture of IPC, PMA-treated cardiomyocytes and those pre-treated with adenosine ( Figure 5B and C). In contrast to IPC and adenosine treatment, diazoxide did not significantly delay contractile failure. However, the increased contractile recovery and reduced hypercontracture associated with diazoxide pre-treatment were both attenuated by Tat-PKCε-IP.
Cardioprotection by direct activation of K ATP channels using a 5 minute pre-treatment of 50μmol/L pinacidil was not significantly affected by PKCε inhibition. These findings confirmed our hypothesis that early opening of sarcoK ATP channels during ischemia is not part of the mechanism of PKC-dependent cardioprotection.
The protection afforded by cardioprotective stimuli preserves mitochondrial function during SFT-MI.
Activation of PKCε by IPC has been demonstrated to cause a translocation of this isoform to mitochondria [14] . To investigate whether the cardioprotective stimuli used in this study Figure 7B shows similar example data for 5 IPC cardiomyocytes, however in this recording 4 out of 5 cardiomyocytes recovered a contractile phenotype. Similar to the contractile recovery in figure 1 , the percentage of cardiomyocytes recovering Ca 2+ -transients was markedly increased after cardioprotective stimuli ( Figure 7C ). The mean time to Ca 2+ -transient failure,
together with contractile and action potential failure times, are plotted in Figure 6D demonstrating that, as would be expected, all of these events occurred concurrently, irrespective of the measurement of contractile function employed.
Additionally, the depletion of intracellular ATP ( Figure 8A and B), as measured using an increase in free intracellular Mg 2+ as a surrogate marker for ATP depletion, was less pronounced after cardioprotective stimuli. Finally, the time to mitochondrial depolarization during metabolic inhibition, as measured by the time at which basal fluorescence was increased to 10% of the maximum, was markedly delayed after cardioprotective stimuli ( Figure 8C to E).
Together, these data show that mitochondrial function is preserved for longer during the simulated ischemia, so preserving intracellular ATP, thus delaying the opening of sarcoK ATP during metabolic inhibition. These findings are consistent with the hypothesis that opening of the sarcoK ATP channel does not play a significant role in cardioprotection.
Discussion
The literature suggests that sarcoK ATP channels are of fundamental importance in the myocardium with evidence suggesting that Kir6.2 plays a key role in IPC [20, 21] The delay in contractile failure was also shown to be PKCε-dependent.
Further evidence supporting a delay in sarcoK ATP activation was provided by action potential measurements, where the time to failure was increased following cardioprotection.
Consistent with these data was the hyperpolarization of the membrane potential seen prior to contractile or action potential failure, again suggesting a contribution of a K + current to contractile failure; which we hypothesized was carried by sarcoK ATP channels. Finally, direct measurement of the time to sarcoK ATP channel activation in cell-attached patch recording confirmed that the sarcoK ATP channel does indeed open later after cardioprotection.
These data, along with previous findings by others [34, 35] , demonstrate that an early opening of sarcoK ATP is not part of the PKCε-dependent cardioprotective processes. Here we demonstrate that sarcoK ATP opening is actually delayed suggesting that the channel is responding to, rather than causative, of the ATP preservation after cardioprotection.
Cardioprotection by pinacidil.
It is important to note that our data suggests that pinacidil pre-treatment imparts cardioprotection via a different mechanism to that involving PKC activation. during MI. We hypothesize that, although the pre-treatment stimulus with pinacidil was washed off, there was still either a residual amount of pinacidil within the membrane or bound to channels so contributing a larger than control K ATP channel current as evident with a shorted APD and more hyperpolarized membrane potential (Figure 4 ).
Cardioprotection by diazoxide does not delay the time to sarcoK ATP channel activation.
Diazoxide-induced cardioprotection bore all of the hallmarks of a classic protected phenotype, including sensitivity to PKCε inhibition; however the time to sarcoK ATP channel activation (and hence contractile failure) was not significantly increased compared to control.
This initially puzzling finding may be explained by a clearer understanding of diazoxide pharmacology. Diazoxide has been widely reported as a mitoK ATP channel specific opener, however it has also been reported that the sarcoK ATP channel may be activated by diazoxide under conditions of reduced ATP, or elevated ADP, such as occur in ischemia [36] . It was hypothesized that diazoxide may reduce the ATP, or increase the ADP, sensitivity of sarcoK ATP channels directly. Indeed it has been reported that if diazoxide is perfused as a 5 minute pretreatment, then the sarcoK ATP channel actually opens earlier than in control cardiomyocytes [28] . If this hypothesis were correct, under normal physiological conditions the channel would remain closed in the presence of diazoxide, but during ischemia sarcoK ATP channels would require a smaller depletion of ATP to become activated.
As diazoxide has been shown to protect via a PKCε-dependent mitochondrial mechanism [37] , the time to ATP depletion would be delayed, making interpretation difficult. In our findings presented in figure 1 , there was a trend towards a delay in contractile failure after diazoxide pre-treatment, however this was not significant compared to control cells (148.3±4.7 vs 173.4±4.6 s, n=6 (≥93 cells), p=0.176). This non-significant delay of contractile failure may represent opening of sarcoK ATP channels at a higher ATP concentration than would be seen in control cardiomyocytes despite the rate at which ATP depletion occurs being slowed after diazoxide treatment [28] .
Evidence for a role of sarcoK ATP channel subunits in cardioprotection.
Whilst our data suggests that the opening of K ATP at the sarcolemmal membrane may not be a key determinant of the protection afforded by the cardioprotective stimuli tested here, there is evidence that sarcoK ATP channels are fundamentally important to cardiomyocyte survival.
Evidence from knockout animal models for Kir6.2 has demonstrated that ischemic preconditioning does not occur in these animals [20, 21] . Rather than contributing effect at the sarcolemma, there is a suggestion that Kir6.2 may be trafficked to the mitochondria on activation by cardioprotective stimuli [38] . These findings suggest that intracellular effects of Kir6.2 redistribution, rather than merely opening as part of the sarcoK ATP channel complex at the cell surface, may be of importance. Indeed, our data in Figure 7 demonstrated that the measured 'mitochondrial parameters' of cardioprotection, ATP level and mitochondrial membrane potential, were preserved for longer after cardioprotection and we cannot exclude trafficking of Kir6.2 to the mitochondria as part of the protective mechanism. The mitoK ATP channel, hypothesized to open in conditions of metabolic stress to preserve the mitochondrial function, may be a key determinant in cardioprotection [39] . Pharmacological evidence, using the classical mitoK ATP channel agents diazoxide and 5-HD, would suggest that mitoK ATP channels do indeed play a role; however the specificity of these agents has been called into question [23] . The recent identification of ROMK as a putative mitoK ATP channel subunit [24] provides a potential target for further investigation. Additionally, the role of sarcoK ATP channels in cardioprotection may be as part of a larger signalasome-type complex [40] . [44] and glimepiride [45] , is markedly attenuated by elevated intracellular
[ADP] [25] as would be found in the sub-sarcolemmal environment during ischemia.
SarcoK ATP is an abundantly expressed myocardial ion channel, but our data suggests that an early opening of the channel does not contribute to the protection afforded by a number of PKC-dependent cardioprotective stimuli, as had been previously hypothesized, although it is clear that the opening of the sarcoK ATP channel does occur when ATP concentrations have fallen far enough. We believe, as was originally suggested for these channels, that sarcoK ATP channel opening is the last opportunity the cardiomyocyte has to reduce ATP consumption and limit the potential damage from [Ca 2+ ] i overload. These data suggest that this property is distinct from the earlier acting mechanisms of cardioprotection, which appear to preserve mitochondrial function for longer during an ischemic insult.
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